Literature DB >> 8823569

Progression of ulcerative proctosigmoiditis: incidence and factors influencing progression.

R C Ayres1, C D Gillen, R S Walmsley, R N Allan.   

Abstract

OBJECTIVE: To assess the changing distribution of disease within the large bowel in patients presenting with ulcerative proctitis or proctosigmoiditis. To evaluate the influence of clinical exacerbations, smoking, parity and family history in disease extension.
DESIGN: Retrospective single-centre study in a university hospital.
METHODS: Case records of patients presenting over a 40-year period were examined to evaluate the clinical course and disease distribution from initial presentation to final follow-up. For each patient whose disease extended to the more proximal colon, an age- and sex-matched control patient was identified whose disease remained confined to the original site. Patients completed a questionnaire to provide information on family history, smoking and parity. The differences in clinical exacerbations, family history, smoking and parity were then compared between the two groups.
RESULTS: Among 145 patients presenting with proctitis or proctosigmoiditis followed prospectively for a median period of 10.9 years, the disease extended in 53 patients. Using actuarial methods the disease progressed beyond the rectosigmoid area in 16% of patients at 5 years and 31% at 10 years. Among the patients whose disease progressed, progression was preceded in 68% of cases by a clinical exacerbation of the colitis. When patients whose disease progressed were compared with those whose disease remained confined to the original site, no differences were detected in the number of clinical exacerbations, smoking habit, family history or parity.
CONCLUSIONS: The factors that are associated with the extension of colitis are probably different from those that predisposed an individual to develop inflammatory bowel disease initially.

Entities:  

Mesh:

Year:  1996        PMID: 8823569     DOI: 10.1097/00042737-199606000-00011

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Ulcerative Colitis: Are We Neglecting Its Progressive Character.

Authors:  Paulo Massinha; Francisco Portela; Sara Campos; Gabriela Duque; Manuela Ferreira; Sofia Mendes; Ana Margarida Ferreira; Carlos Sofia; Luís Tomé
Journal:  GE Port J Gastroenterol       Date:  2017-10-20

2.  Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort.

Authors:  Johan Burisch; Ryan Ungaro; Ida Vind; Michelle V Prosberg; Flemming Bendtsen; Jean-Frederic Colombel; Marianne K Vester-Andersen
Journal:  J Crohns Colitis       Date:  2017-10-01       Impact factor: 9.071

3.  Factors associated with disease evolution in Greek patients with inflammatory bowel disease.

Authors:  Constantinos Chatzicostas; Maria Roussomoustakaki; Spiros Potamianos; Gregorios Paspatis; Ioannis Mouzas; John Romanos; Helen Mavrogeni; Elias Kouroumalis
Journal:  BMC Gastroenterol       Date:  2006-07-25       Impact factor: 3.067

4.  Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis.

Authors:  Xiaojing Zhao; Changcheng Zhou; Jingjing Ma; Yunjuan Zhu; Min Sun; Peixue Wang; Yi Zhang; Haiqin Ma; Hongjie Zhang
Journal:  Sci Rep       Date:  2017-04-25       Impact factor: 4.379

5.  Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.

Authors:  Makoto Naganuma; Nobuo Aoyama; Tomohiro Tada; Kiyonori Kobayashi; Fumihito Hirai; Kenji Watanabe; Mamoru Watanabe; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2017-08-04       Impact factor: 7.527

6.  Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.

Authors:  Gyorgy Kovacs; Nora Sipeki; Boglarka Suga; Tamas Tornai; Kai Fechner; Gary L Norman; Zakera Shums; Peter Antal-Szalmas; Maria Papp
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

Review 7.  When disease extent is not always a key parameter: Management of refractory ulcerative proctitis.

Authors:  Georgios Michalopoulos; Konstantinos Karmiris
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-12-11

8.  Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.

Authors:  Makoto Naganuma; Nobuo Aoyama; Yasuo Suzuki; Haruo Nishino; Kiyonori Kobayashi; Fumihito Hirai; Kenji Watanabe; Toshifumi Hibi
Journal:  J Crohns Colitis       Date:  2015-11-16       Impact factor: 9.071

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.